Physician profile
Milena Pavlova
NPI 1043276306
$23,249.70
in general payments reported to CMS, 2019-2025
11 companies · $4,626 in 2025
The $4,626 reported for 2025 was more than what 86% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $2,820 · 2021: $3,000 · 2022: $2,705 · 2023: $274 · 2024: $9,594 · 2025: $4,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,302 · Consulting Fee: $4,446 · Food and Beverage: $916 · Travel and Lodging: $829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,302.00 |
| Consulting Fee | $4,446.00 |
| Food and Beverage | $916.39 |
| Travel and Lodging | $828.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $17,184.30 | 2019-2025 | |
| Genzyme Corporation | $2,820.00 | 2020 | |
| Pear Therapeutics (US), INC. | $1,700.00 | 2022 | |
| Biogen, INC. | $909.69 | 2022 | |
| Harmony Biosciences LLC | $222.92 | 2022-2025 | |
| Zoll Respicardia, INC. | $180.63 | 2023 | Remede System |
| Idorsia Pharmaceuticals US INC | $113.13 | 2024 | Quviviq |
| Livanova USA, INC. | $65.22 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $31.09 | 2019 | |
| Sunovion Pharmaceuticals INC. | $22.72 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milena Pavlova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.